Nicholas DeVito, Assistant Professor in the Division of Medical Oncology at Duke Cancer Institute, shared a post on LinkedIn:
“‘Chris wasn’t even 10 [years old] and U.S. government funding was already working toward his cure,’ Nicholas DeVito, Biggar’s oncologist and assistant. professor in the division of medical oncology at Duke Cancer Institute, said to The Cancer Letter.
‘So, what are we risking in 30 years by cutting NIH funding today? Good thing we were prioritizing it in the 90s, because that progress gave us the tools we needed to treat Chris the right way, up front, with the standard of care, since the science and trials had already been done.’
Chris’ story of overcoming Stage IV MSI-H Colorectal cancer with immunotherapy is a pristine example of the importance and urgency of robust NIH and NCI funding. This is excellent coverage by The Cancer Letter on the efforts by Patient Action for Cancer Research to protect and promote NCI funding.”
More posts featuring Nicholas DeVito.
